Autologous stem cell transplant and combination immunotherapy of rituximab and interferon-α induces prolonged clinical and molecular remissions in patients with follicular lymphoma

Br J Haematol. 2019 Feb;184(3):469-472. doi: 10.1111/bjh.15118. Epub 2018 Jan 30.

Authors

Affiliations

¹ Division of Haematology, Department of Medicine, Sunnybrook Health Science Centre/University of Toronto, Toronto, Ontario, Canada.
² Laboratory Medicine; University of Toronto, Laboratory Medicine and Pathobiology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.

PMID: 29380359
DOI: 10.1111/bjh.15118

No abstract available

Keywords: autologous stem cell transplant; follicular lymphoma; interferon; minimal residual disease; rituximab.

Publication types

Letter

MeSH terms

Autografts
Disease-Free Survival
Female
Hematopoietic Stem Cell Transplantation*
Humans
Immunotherapy*
Interferon-alpha / administration & dosage*
Lymphoma, Follicular / mortality*
Lymphoma, Follicular / therapy*
Male
Middle Aged
Remission Induction
Rituximab / administration & dosage*
Survival Rate

Substances

Interferon-alpha
Rituximab